Technical Data
p47 phox (NCF1, NOXO2, p47phox, neutrophil cytosolic factor 1, 47kD, chronic granulomatous disease, autosomal 1, Neutrophil cytosolic factor-1 (47kD)
Activation of NADPH-oxidase dependent superoxide generation requires the participation of several cytosolic factors including p47phox, p67phox, p40phox and Rac (1 or 2). In the resting cell, p47phox, p67phox, and p40phox form a large molecular weight complex which can be recovered from the cytosolic fraction. Activation of the NADPH oxidase is initiated by the assembly of p47phox, p67phox, and Rac with cytochrome b558 in a 1:1:1:1 complex in the plasma membrane. p47phox, p67phox, and Rac exhibit cooperative binding, since increasing the concentration of any one component lowers the EC50 of the other components. A great deal of current research involves understanding the protein protein interactions, and how these change with the activation state.

Suitable for use in Western Blot. Other applications not tested.

Recommended Dilutions:
Western Blot: 0.5-2ug/ml detected p47-phox in RIPA lysates from RAW 264.7 cells.
Optimal dilutions to be determined by the researcher.

Recommended Secondary Antibodies:
I1904-39: IgG, X-Adsorbed (HRP) Pab Gt xRb
I1904-40A: IgG, H&L, X-Adsorbed (HRP) Pab Gt xRb
I1904-46Q: IgG, H&L (HRP) Pab Gt xRb

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceMouseRabbit
Synthetic peptides containing the first 15 amino acids of the N-terminal and the last 15 amino acids of the C-terminus of mouse p47-phox, conjugated to KLH.
Purified by Protein A affinity chromatography.
Supplied as a liquid in 0.1M Tris-glycine, pH 7.4, 0.15M sodium chloride, 0.05% sodium azide, before the addition of glycerol to 30%.
Recognizes mouse p47-phox, Mr ~47kD.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Ellson, Chris, et al. (2006). EMBO J. 25:4468- 78. 2. Ellson, Chris D., et al. (2006). J Exp Med. 203:1927-37. 3. Jackson, et al. (1999). Immunogenetics. 39: 272-275.